RBB

Hendrik Meder

Hendrik Meder is an Associate Principle at RBB Economics based in Brussels. He has nearly 10 years’ experience in competition economics and empirical assessment in the public and private sector.

Prior to joining RBB in early 2024, Hendrik was a member of the Chief Economist Team at the Directorate General for Competition, European Commission. He advised case teams and the Chief Economist in economic and quantitative assessments of several high-profile mergers and antitrust cases.

Hendrik holds a PhD from the KU Leuven and as a German national, he is fluent in German and English.

In his role as a member of the Chief Economist Team (CET) of the DG Competition of the European Commission, Hendrik investigated and advised case teams on several high-profile merger cases in Phase I and Phase II proceedings, as well antitrust cases and competition policy matters. He reported directly to the Chief Economist and case management level and cooperated with several jurisdictions and antitrust authorities outside the EU.

His experience covers a wide range of sectors. He is particularly specialised in the airlines industry, high-tech manufacturing, telecommunications, online platforms and the pharmaceutical sector.

During his doctoral studies, Hendrik focused his research on the relationship of mergers and acquisition and pharmaceutical innovation. He presented and discussed innovation aspects in merger proceedings in the context of EU merger control at international academic conferences and seminars.

Selected Cases

  • Booking/eTraveli

    Merger, EU

  • Siemens/Alstom

    Merger, EU

  • IAG/Air Europa

    Merger, EU

  • Air Canada/Transat

    Merger, EU

  • Korean Air/Asiana

    Merger, EU

  • Orange/MasMovil

    Merger, EU

  • Orange/Voo/Brutele

    Merger, EU

  • BMS/Celgene

    Merger, EU

  • Aspen

    Abuse of dominance, EU

  • Trucks cartel

    Follow-on litigation, Germany & EU

A global network of experienced experts

Our 230-strong, multi-lingual team, spread across 16 offices, has managed over 3,000 cases in 120+ countries, advising on more than one-third of EU Phase II cases in the last 5 years.